DURHAM, N.C., Oct. 30, 2013 /PRNewswire/ -- Scioderm, Inc. was honored with the Partners in Progress Award from the Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA). The award recognized the company's recent work developing SD-101, which is a topical therapy being developed to treat the severe skin effects seen in patients with inherited Epidermolysis Bullosa (EB), a rare, genetic, connective tissue disorder for which there is no treatment or cure. Dr. Robert Ryan, CEO, and Robert Coull, COO of Scioderm, accepted the award during the recent 15th Annual DEBRA of America Benefit at The Museum of Modern Art in New York City.
"Scioderm is a perfect example of a company that is making significant progress in the development of a potential therapy for EB while being a strong partner and advocate for the EB community," said Brett Kopelan, Executive Director of DEBRA of America. "Giving Scioderm the Partners in Progress award was an incredible honor for me and I look forward to years of us working together to help the EB community."
"We are honored to be recognized by DEBRA for our team's efforts," said Dr. Robert Ryan, President and Chief Executive Officer of Scioderm. "Our focus is working with the DEBRA organization towards raising awareness of the disease, and developing a treatment that can help those suffering from this painful and debilitating genetic blistering disorder."
About Epidermolysis Bullosa (EB)
Epidermolysis Bullosa (EB) is a rare genetic connective tissue condition that, in all of its forms, share the prominent manifestation of extremely fragile skin that blisters or tears with the slightest friction or trauma. This particular manifestation has led to EB patients being known as "Butterfly children" due to the analogous nature of the fragility of the skin to the wings of a butterfly. As of today there is no cure or effective treatment. Daily wound care, pain management and preventative bandaging are the only options available for caregivers, who are usually the parents or other family members. The more severe forms of the disease lead to scarring, disfigurement, disability and early death, usually before the age of 30.
About DEBRA of America
The Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA), is the only national non-profit dedicated to funding research and providing services and programs for those with Epidermolysis Bullosa (EB) – The Worst Disease You've Never Heard Of.™
About Scioderm, Inc.
Scioderm is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address diseases with critical unmet medical needs, including orphan products. The company is headquartered in Durham, North Carolina. The lead product, SD-101, is a topical cream that has previously demonstrated potential to provide improvement in treating the severe skin effects seen in patients across all EB subtypes. Additional information about Scioderm can be found at www.sderm.com.
Scioderm Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Scioderm disclaims any intent or obligation to update these forward-looking statements.
Chief Operating Officer
SOURCE Scioderm, Inc.